Systematic review: Serum autoantibodies in the early detection of gastric cancer

International Journal of Cancer

Volumn 136, Issue 10, 2015, Pages 2243-2252

  Werner, Simone ^a   Chen, Hongda ^a   Tao, Sha ^a   Brenner, Hermann ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

autoantibodies; biomarker; blood test; early detection; gastric cancer; screening; systematic review; TAA

Indexed keywords

AUTOANTIBODY; CANCER ANTIBODY;

ANTIBODY DETECTION; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; DATA BASE; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEROLOGY; STOMACH CANCER; SYSTEMATIC REVIEW; WESTERN BLOTTING; BIBLIOGRAPHIC DATABASE; BLOOD; IMMUNOLOGY; PROCEDURES; STOMACH NEOPLASMS;

ANTIBODIES, NEOPLASM; AUTOANTIBODIES; DATABASES, BIBLIOGRAPHIC; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS;

EID: 84924488541     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28807     Document Type: Article

References (59)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Hiripi E, Jansen L, Gondos A, et al. Survival of stomach and esophagus cancer patients in Germany in the early 21st century. Acta Oncol 2012; 51: 906-14.
3. Hamashima C, Shibuya D, Yamazaki H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2008; 38: 259-67.
4. Miki K,. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels-"ABC method". Proc Jpn Acad Ser B Phys Biol Sci 2011; 87: 405-14.
5. Kato M, Asaka M,. Recent development of gastric cancer prevention. Jpn J Clin Oncol 2012; 42: 987-94.
6. Tan HT, Low J, Lim SG, et al. Serum autoantibodies as biomarkers for early cancer detection. FEBS J 2009; 276: 6880-904.
7. Heo CK, Bahk YY, Cho EW,. Tumor-associated autoantibodies as diagnostic and prognostic biomarkers. BMB Rep 2012; 45: 677-85.
8. Farlow EC, Patel K, Basu S, et al. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res 2010; 16: 3452-62.
9. Zhang JY, Casiano CA, Peng XX, et al. Enhancement ot antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003; 12: 136-43.
10. Koziol JA, Zhang JY, Casiano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003; 9: 5120-6.
11. Looi K, Megliorino R, Shi FD, et al. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep 2006; 16: 1105-10.
12. Zhang JY, Chan EK, Peng XX, et al. Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol 2001; 100: 149-56.
13. Megliorino R, Shi FD, Peng XX, et al. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev 2005; 29: 241-8.
14. 2+ binding protein Calnuc is a potential marker in colon cancer detection. Int J Oncol 2007; 30: 1137-44.
15. Klaamas K, Kurtenkov O, von Mensdorff-Pouilly S, et al. Impact of Helicobacter pylori infection on the humoral immune response to MUC1 peptide in patients with chronic gastric diseases and gastric cancer. Immunol Invest 2007; 36: 371-86.
16. Kurtenkov O, Klaamas K, Mensdorff-Pouilly S, et al. Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival. Acta Oncol 2007; 46: 316-23.
17. Smorodin EP, Kurtenkov OA, Sergeyev BL, et al. The relation of serum anti-(GalNAc beta) and -para-Forssman disaccharide IgG levels to the progression and histological grading of gastrointestinal cancer. Exp Oncol 2007; 29: 61-6.
18. Fujita Y, Nakanishi T, Miyamoto Y, et al. Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett 2008; 263: 280-90.
19. Tsunemi S, Nakanishi T, Fujita Y, et al. Proteomics-based identification of a tumor-associated antigen and its corresponding autoantibody in gastric cancer. Oncol Rep 2010; 23: 949-56.
20. Shimada H, Ochiai T, Nomura F,. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer 2003; 97: 682-9.
21. Shimada H, Kuboshima M, Shiratori T, et al. Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol 2007; 30: 97-103.
22. Muller M, Meyer M, Schilling T, et al. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers. Int J Oncol 2006; 29: 973-80.
23. Kang XD, Zhang L, Sun J, et al. Prohibitin: a potential biomarker for tissue-based detection of gastric cancer. J Gastroenterol 2008; 43: 618-25.
24. Wu M, Mao C, Chen Q, et al. Serum p53 protein and anti-p53 antibodies are associated with increased cancer risk: a case-control study of 569 patients and 879 healthy controls. Mol Biol Rep 2010; 37: 339-43.
25. Mattioni M, Soddu S, Porrello A, et al. Serum anti-p53 antibodies as a useful marker for prognosis of gastric carcinoma. Int J Biol Markers 2007; 22: 302-6.
26. Zayakin P, Ancans G, Silina K, et al. Tumor-associated autoantibody signature for the early detection of gastric cancer. Int J Cancer 2013; 132: 137-47.
27. Xu QW, Zhao W, Wang Y, et al. An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer. Cancer Res 2012; 72: 6351-61.
28. Qiu LL, Hua PY, Ye LL, et al. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China. Cancer Detect Prev 2007; 31: 45-9.
29. Yu DH, Li JH, Wang YC, et al. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients. Clin Chim Acta 2011; 412: 930-5.
30. Zeng G, Aldridge ME, Wang Y, et al. Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker. Int J Cancer 2005; 114: 268-73.
31. Nakamura H, Hinoda Y, Nakagawa N, et al. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J Gastroenterol 1998; 33: 354-61.
32. Zhou JH, Zhang B, Kernstine KH, et al. Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma. World J Gastroenterol 2011; 17: 1373-8.
33. Fujiwara S, Wada H, Kawada J, et al. NY-ESO-1 antibody as a novel tumour marker of gastric cancer. Br J Cancer 2013; 108: 1119-25.
34. Chen X, Dong K, Long M, et al. Serum anti-AEG-1 auto-antibody is a potential novel biomarker for malignant tumors. Oncol Lett 2012; 4: 319-23.
35. Wurl P, Weigmann F, Meye A, et al. Detection of p53 autoantibodies in sera of gastric cancer patients and their prognostic relevance. Scand J Gastroenterol 1997; 32: 1147-51.
36. Shiota G, Ishida M, Noguchi N, et al. Clinical significance of serum P53 antibody in patients with gastric cancer. Res Commun Mol Pathol Pharmacol 1998; 99: 41-51.
37. Shimizu K, Ueda Y, Yamagishi H,. Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients. Gastric Cancer 2005; 8: 214-9.
38. Wu CW, Lin YY, Chen GD, et al. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. Br J Cancer 1999; 80: 483-8.
39. He Y, Wu Y, Mou Z, et al. Proteomics-based identification of HSP60 as a tumor-associated antigen in colorectal cancer. Proteomics Clin Appl 2007; 1: 336-42.
40. Kamei M, Kato M, Mochizuki K, et al. Serodiagnosis of cancers by ELISA of anti-histone H2B antibody. Biotherapy 1992; 4: 17-22.
41. Zhou SF, Xie XX, Bin YH, et al. Identification of HCC-22-5 tumor-associated antigen and antibody response in patients. Clin Chim Acta 2006; 366: 274-80.
42. Maehara Y, Kakeji Y, Watanabe A, et al. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer 1999; 85: 302-8.
43. Schmetzer O, Moldenhauer G, Riesenberg R, et al. Quality of recombinant protein determines the amount of autoreactivity detected against the tumor-associated epithelial cell adhesion molecule antigen: low frequency of antibodies against the natural protein. J Immunol 2005; 174: 942-52.
44. Xia Q, Kong XT, Zhang GA, et al. Proteomics-based identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer. Biochem Biophys Res Commun 2005; 330: 526-32.
45. Kestler DP, Foster JS, Macy SD, et al. Expression of odontogenic ameloblast-associated protein (ODAM) in dental and other epithelial neoplasms. Mol Med 2008; 14: 318-26.
46. Song MH, Ha JC, Lee SM, et al. Identification of BCP-20 (FBXO39) as a cancer/testis antigen from colon cancer patients by SEREX. Biochem Biophys Res Commun 2011; 408: 195-201.
47. Konstadoulakis MM, Syrigos KN, Albanopoulos C, et al. The presence of anti-carcinoembryonic antigen (CEA) antibodies in the sera of patients with gastrointestinal malignancies. J Clin Immunol 1994; 14: 310-3.
48. Ziegler A, Konig IR, Schulz-Knappe P,. Challenges in planning and conducting diagnostic studies with molecular biomarkers. Dtsch Med Wochenschr 2013; 138: e2-24.
49. Ziegler A, Koch A, Krockenberger K, et al. Personalized medicine using DNA biomarkers: a review. Hum Genet 2012; 131: 1627-38.
50. Kijanka G, Murphy D,. Protein arrays as tools for serum autoantibody marker discovery in cancer. J Proteomics 2009; 72: 936-44.
51. UniProt Consortium. UniProt Knowledgebase. http://www.uniprot.org/, last accessed January 31, 2014.
52. Graham JB, Graham RM,. Antibodies elicited by cancer in patients. Cancer 1955; 8: 409-16.
53. Gold P,. Circulating antibodies against carcinoembryonic antigens of the human digestive system. Cancer 1967; 20: 1663-7.
54. Ademokun A, Wu YC, Dunn-Walters D,. The ageing B cell population: composition and function. Biogerontology 2010; 11: 125-37.
55. Rutjes AW, Reitsma JB, Di Nisio M, et al. Evidence of bias and variation in diagnostic accuracy studies. CMAJ 2006; 174: 469-76.
56. Babel I, Barderas R, Diaz-Uriarte R, et al. Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol Cell Proteomics 2009; 8: 2382-95.
57. Babel I, Barderas R, Diaz-Uriarte R, et al. Identification of MST1/STK4 and SULF1 proteins as autoantibody targets for the diagnosis of colorectal cancer by using phage microarrays. Mol Cell Proteomics 2011; 10:M110.001784.
58. Pedersen JW, Blixt O, Bennett EP, et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int J Cancer 2011; 128: 1860-71.
59. Chapman CJ, Healey GF, Murray A, et al. EarlyCDT(R)-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol 2012; 33: 1319-26.